You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
McKinsey
Boehringer Ingelheim
Express Scripts

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

PLENVU Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Plenvu patents expire, and when can generic versions of Plenvu launch?

Plenvu is a drug marketed by Salix and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seven patent family members in thirty-five countries.

The generic ingredient in PLENVU is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.

US ANDA Litigation and Generic Entry Outlook for Plenvu

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for PLENVU
Drug Prices for PLENVU

See drug prices for PLENVU

Recent Clinical Trials for PLENVU

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Istituto Clinico HumanitasPhase 4
Quotient ClinicalPhase 1
NorginePhase 1

See all PLENVU clinical trials

Recent Litigation for PLENVU

Identify potential future generic entrants

District Court Litigation
Case NameDate
BAUSCH HEALTH IRELAND LIMITED v. LUPIN INC.2019-04-01
Bausch Health Ireland Limited v. Lupin Ltd.

See all PLENVU litigation

Paragraph IV (Patent) Challenges for PLENVU

US Patents and Regulatory Information for PLENVU

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Colorcon
Merck
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.